NMRD - Nemaura Medical Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
7.25
+0.50 (+7.41%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Williams %R

Williams %R

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close6.75
Open6.71
Bid5.05 x 1400
Ask8.50 x 1200
Day's Range6.56 - 7.29
52 Week Range2.50 - 14.80
Volume35,253
Avg. Volume34,143
Market Cap150.86M
Beta (5Y Monthly)-0.57
PE Ratio (TTM)N/A
EPS (TTM)-0.21
Earnings DateFeb 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Business Wire

    Nemaura Medical 2020 Stock Incentive Plan Approved at Annual General Meeting

    Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, today announced its 2020 Omnibus Incentive Plan ("Plan") was approved by shareholder vote at the Company’s Annual General Meeting on May 15, 2020. A maximum of 1,000,000 shares of Common Stock have been made available for Awards under the Plan.

  • Business Wire

    Nemaura reports positive data from early head-to-head comparison with a major incumbent CGM Device

    Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced positive initial user-volunteer data from its head-to-head comparison with a major incumbent CGM device.

  • Business Wire

    Nemaura Medical Announces Interview with CEO to Air on May 11

    Nemaura Medical Announces Interview with CEO to Air on May 11

  • Business Wire

    Nemaura Secures $5 Million Loan to Accelerate Commercial Strategy

    Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), today announced it has secured a 24-month, $5 million non-convertible loan. The loan does not include warrants or other equity securities.

  • Business Wire

    Nemaura Plans To Launch Body-Worn Continuous Temperature Monitor (CTM) to Track Fever Caused by Viral Infections such as COVID-19

    Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), announced plans for a new product line by seeking to immediately repurpose sugarBEAT® as a CTM since its inbuilt temperature sensor is capable of continuously tracking body temperature through the skin. Nemaura is considering various options to expedite the launch of a CTM, including potential partnerships and direct to consumer sales.

  • Nemaura Medical: The Potential proBEAT Launch Adds Some Steam
    GuruFocus.com

    Nemaura Medical: The Potential proBEAT Launch Adds Some Steam

    The med-tech company is planning to launch a new digital health care subscription service Continue reading...

  • Business Wire

    Nemaura to Launch New Digital Brand proBEAT™ in the USA, Targeting a Market of Over 100 Million Potential Users With Its Prescription-Free Consumer Wellness Glucose Monitoring Device and Digital Healthcare Subscription Service

    Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.

  • Nemaura Medical: A Diabetes-Oriented Med-Tech Play
    GuruFocus.com

    Nemaura Medical: A Diabetes-Oriented Med-Tech Play

    The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum Continue reading...

  • Nemaura Medical Launches Non-Invasive Glucose Monitor in the US
    Newsfile

    Nemaura Medical Launches Non-Invasive Glucose Monitor in the US

    FDA feedback leads to continuous glucose monitor placement into the wellness device category New York, New York--(Newsfile Corp. - March 20, 2020) - Small Caps Daily recently published an article on Nemaura Medical, Inc. (NASDAQ: NMRD), after the Company's latest surge in press coverage, piqued the publication's interest. The media interest is warranted, as it surrounds the preparations for the launch of Nemaura Medical's non-invasive and flexible continuous glucose monitor ("CGM"), sugarBEAT® in the U.S., ...

  • Business Wire

    Nemaura To Prepare for Launch of sugarBEAT® CGM In the U.S. Following FDA Feedback

    Nemaura Medical Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it is preparing for the launch of sugarBEAT® in the U.S. under the wellness category following recent feedback from the U.S. Food and Drug Administration (the "FDA"). The Company is prioritizing launch plans in the U.S. and is considering various options to expedite the launch, including potential partnering in continuation of its on-going discussions with multi-national companies.

  • Business Wire

    Nemaura Medical Enters Into Multiple Verbal Non-Binding Agreements for its sugarBEAT® Platform

    Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and pre-diabetes through personalized lifestyle coaching, announced it has entered in to multiple verbal non-binding agreements for sugarBEAT® with the aim of securing regional and global partnerships.

  • Business Wire

    Nemaura Medical Launches sugarBEAT® App on Play Store Ahead of its Planned Commercial Launch of BEAT®diabetes Subscription Service

    Nemaura Medical, Inc. (NASDAQ: NMRD) ("Nemaura" or the "Company"), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and currently commercializing sugarBEAT®, its non-invasive and flexible continuous glucose monitor ("CGM"), together with BEAT®diabetes, a planned health subscription service designed to help people with Type 2 diabetes and prediabetes through personalized lifestyle coaching, launched its sugarBEAT® App for Android devices on the Play Store in preparation for the planned launch of the Company’s BEAT®diabetes subscription based service expected for next month.1

  • GlobeNewswire

    Nemaura Medical Reports Results and Provides Business Update for the Third Quarter Ended December 31, 2019

    The Company announced a partnership with the award-winning UK-based company, Changing Health, to bring digital behavior programs to improve the management, reversal and prevention of Type 2 diabetes in multiple territories commencing with the United Kingdom and Ireland. Changing Health is a provider of digital coaching services to the National Health Service England, aimed at the prevention or reversal of Type 2 diabetes.

  • GlobeNewswire

    Nemaura Provides 2019 Year-End Corporate Update

    Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor (CGM), together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, today provided a 2019 year-end corporate update. The company started the first phase of our commercial launch of sugarBEAT® in the United Kingdom with the first shipments of sugarBEAT® CGM devices to diabetic and pre-diabetic patients from whom positive user feedback has been received.

  • GlobeNewswire

    Nemaura Medical and Changing Health announce Partnership to provide award-winning Diabetes Behavioral Change services

    Loughborough, England, Dec. 17, 2019 --   Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible.

  • GlobeNewswire

    Nemaura Medical announces expansion of SugarBEAT® offering  with BEAT® Diabetes digital subscription services

    Loughborough, England, Dec. 05, 2019 --  Nemaura Medical, Inc. (NASDAQ:NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a.

  • GlobeNewswire

    Nemaura Medical Announces 1 for 10 Reverse Split Intended to Attract a Wider Universe of Institutional Investors

    The reverse split is expected to take effect at the market open on December 5, 2019. In accordance with the reverse split, each stockholder’s percentage ownership interest in Nemaura Medical remains unchanged. Any fractional shares resulting from the reverse stock split were rounded up to the nearest whole share of common stock.

  • Benzinga

    The Daily Biotech Pulse: Reata, Kadmon Clinical Readouts, Apyx Medical's Earnings Beat

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 11) ACADIA Pharmaceuticals Inc (NASDAQ: ACAD ) Agenus Inc ...

  • GlobeNewswire

    Nemaura Medical Reports Results and Provides Business Update for the Second Quarter Ended September 30, 2019

    Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) --  – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the second quarter ended September 30, 2019. Dr. Faz Chowdhury, CEO of Nemaura commented, “This has been an exciting period for Nemaura as we officially commenced the commercial rollout plans for SugarBEAT® following our recent CE approval. As the world’s first non-invasive, safe, needle-free CGM, SugarBEAT® is uniquely positioned to target the underserved $80 billion market for Type 2 diabetics and pre-diabetics.

  • GlobeNewswire

    Nemaura Medical Provides Update Regarding Commercial Launch of SugarBEAT® and First Patient User Experiences as Presented at EASD Symposia 2019 in Barcelona

    Loughborough, England, Oct. 03, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today provided an update regarding the commercial launch of SugarBEAT® and feedback from its first patient user experiences as presented at the recent symposia hosted by Nemaura  at the 55th Annual Meeting of the European Association for the Study of Diabetes (EASD) in Barcelona. Dr. Faz Chowdhury, Chief Executive Officer, discussed key milestones in the development and plans for the commercial rollout program for SugarBEAT® in the UK, Ireland, Germany and other key European markets following its recent CE mark approval in the European Union.

  • Is Nemaura Medical (NASDAQ:NMRD) In A Good Position To Invest In Growth?
    Simply Wall St.

    Is Nemaura Medical (NASDAQ:NMRD) In A Good Position To Invest In Growth?

    There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...

  • GlobeNewswire

    Nemaura Medical to Hold a Symposia at EASD in Barcelona on Thursday September 19, 2019

    Loughborough, England , Sept. 12, 2019 -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on.

  • GlobeNewswire

    Nemaura Medical Reports Quarterly Results for First Quarter Ended June 30, 2019

    Loughborough, England, Aug. 09, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today reported financial results for the first quarter ended June 30, 2019. The credit facility is at 8% interest, with interest payments due quarterly and principal due in full at maturity in five years.  The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. With adequate cash on hand and the credit facility, along with anticipated revenue, Management has instructed Maxim to suspend all ATM activities.

  • GlobeNewswire

    Nemaura Medical Announces First Shipments of SugarBEAT® Devices to Diabetic and Pre-Diabetic Patients as Part of its First Phase of Launch

    Loughborough, England, Aug. 07, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced the first shipments of SugarBEAT® to diabetic and pre-diabetic patients in the United Kingdom. Nemaura Medical will present data from its first users as part of several presentations planned at a symposium being held by the Company at the European Association for the Study of Diabetes (EASD) conference in Barcelona on September 19, 2019.

  • GlobeNewswire

    Nemaura Medical Inc. Announces $8 million Senior Debt Facility Provided by Existing Investors

    Loughborough, England, Aug. 01, 2019 (GLOBE NEWSWIRE) --  Nemaura Medical, Inc. (NMRD), a medical technology company focused on the commercialization of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced an $8 million (USD) senior credit facility from existing major shareholders, with the first $3.5 million available immediately, to help fund the Company’s European commercial launch plans.  The non-dilutive credit facility will carry 8% interest with quarterly payments and the principal due only upon maturity in 5 years.  The credit facility has no stock, warrants, or equity related instruments, or other associated expenses. Dr. Faz Chowdhury, CEO of Nemaura, stated, “Nemaura is at an exciting inflection point, having recently received CE Mark approval for SugarBEAT®, the world’s first non-invasive, needle-free, continuous glucose monitor.  We recently submitted a De Novo 510(k) medical device application to the U.S. Food and Drug Administration for SugarBEAT®.